Amgen Inc. (NASDAQ:AMGN) does about 2.66M shares in volume on a normal day but saw 1849788 shares change hands in Monday trading. The company now has a market cap of 145.75B USD and an enterprise value of about $145.83B. Its current market price is $247.36, marking an increase of 1.10% compared to the previous close of $244.67. The 52 week high reached by this stock is $264.97 whilst the lowest price level in 52 weeks is $177.05. The script in recent trading has seen the stock touch a high of $249.02 and a low of $244.53.

Amgen Inc. (AMGN) has a 20-day trading average at $252.38 and the current price is -6.65% off the 52-week high compared with 39.71% distance from its 52-week low. The 50-day simple moving average of the closing price is $239.14 and its 200-day simple moving average is $227.35. If we look at the stock’s price movements over the week, volatility stands at 2.08%, which increases to 2.41% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 50.48 to suggest the stock is neutral.

The consensus objective for the share price is $262.76, suggesting that the stock has a potential upside of 5.86% over the period.

Raymond James upgraded its price target at $255.

The current price level is -2.16%, 3.63%, and 8.91% away from its SMA20, SMA50, and SMA200 respectively, with the AMGN price moving above the 50-day SMA on August 03. Amgen Inc. (AMGN) stock is down -2.48% over the week and -4.21% over the past month. Its price is 2.61% year-to-date and 32.12% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $4.25 above consensus estimates by $0.43. The company’s next earnings report is expected on 11/03/2020, with forecasts estimating quarterly EPS at $3.8 and $15.76 for whole year. AMGN’s earnings per share are forecast to grow by 6.30% this year and 6.90% over next year. Expected sales for next quarter are $6.63 billion, which analysts say will come at $25.44 billion for the current fiscal year and next year at $26.52 billion. In addition, estimates put the company’s current quarterly revenue at an average of $6.35 billion.

To reach the target analysts have set, the stock logically needs to grow 5.86 percent from here.

Outstanding shares total 588.00M with insiders holding 0.22% of the shares and institutional holders owning 78.93% of the company’s common stock. The company has a return on investment of 21.20% and return on equity of 71.70%. The price to earnings ratio (P/E ratio) amounts to 20.21 while the forward price to earnings ratio is 14.67. The beta has a value of 0.93. Price to book ratio is 13.64 and price to sales ratio is 6.00.

According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Amgen Inc. (AMGN) to 16,766,820 shares, mirroring a recent drop by -2.19%. Vanguard Total Stock Market Index dumped -0.38 million shares of Amgen Inc. common stock bringing its total worth to about $3.95 billion at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard 500 Index Fund, which added 70578.0 shares to end up with 12,204,301 shares worth $2.88 billion. Vanguard PRIMECAP Fund raise their holdings by 1.18% in the company over the course of the most recent quarter. It now holds a 1.79% position in Amgen Inc. thanks to 10.53 million shares amounting to $2.48 billion.